Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.46 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344997 | 0.87 | TSHR (0.46) | FOXO1LMNA | |
| SCHEMBL25069796 | 0.85 | FOXO1 (0.50) | GSK3BFOXO1CHRM1 | |
| SCHEMBL25069325 | 0.84 | FOXO1 (0.54) | GSK3BFOXO1CHRM1LMNA | |
| SCHEMBL25069270 | 0.81 | FOXO1 (0.65) | GSK3BFOXO1LMNA | |
| SCHEMBL1342683 | 0.81 | GSK3B (0.70) | GSK3B | |
| SCHEMBL1344580 | 0.78 | TSHR (0.49) | LMNA | |
| SCHEMBL25069517 | 0.77 | FOXO1 (0.60) | GSK3BFOXO1LMNATOP1 | |
| SCHEMBL25069772 | 0.77 | FOXO1 (0.46) | GSK3BFOXO1LMNATOP1 | |
| SCHEMBL25069747 | 0.77 | FOXO1 (0.52) | GSK3BFOXO1CHRM1LMNA | |
| SCHEMBL25069555 | 0.76 | FOXO1 (0.58) | GSK3BFOXO1LMNATOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-2383271-A1 | Aminoquinolones as GSK-3 Inhibitors | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| EP-2013182-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| WO-2007106537-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885FOXO1 215/4885CHRM1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.